PDS Biotechnology Corporation (PDSB) Dividend History

Company News

• PDSB Loss Improves as Costs Drop

  PDS Biotechnology reported a Q2 2025 net loss of $0.21 per share, beating analyst expectations. The company continues advancing its immunotherapy platforms in oncology and infectious disease, with notable progress in clinical trials for HPV and colorectal cancer treatments.

  The Motley Fool

  Featured Companies: EDGE
• PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  PDS Biotechnology Corporation announced that it granted 7,000 nonstatutory stock options to an employee as a material inducement to employment. The options have an exercise price of $2.25 and vest over a four-year period.

  GlobeNewswire Inc.
• All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy

  PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  Zacks Investment Research
• Analyst Expectations for PDS Biotechnology's Future

  Over the past 3 months, 4 analysts have published their opinion on PDS Biotechnology (NASDAQ:PDSB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 0 0 0 0 0 These 4 analysts have an average price target of $20.75 versus the current ...Full story available on Benzinga.com

  Benzinga
• PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study

  PDS Biotechnology reports positive results in the phase 2 study of PDS0101 with Keytruda for head and neck cancer and plans for the phase 3 study. Find out why PDSB stock is a Buy.

  Seeking Alpha

  Featured Companies: MRK